Efficacy and safety of bimekizumab as add-on therapy for rheumatoid arthritis in patients with inadequate response to certolizumab pegol: a proof-of-concept study
出版年份 2019 全文链接
标题
Efficacy and safety of bimekizumab as add-on therapy for rheumatoid arthritis in patients with inadequate response to certolizumab pegol: a proof-of-concept study
作者
关键词
-
出版物
ANNALS OF THE RHEUMATIC DISEASES
Volume 78, Issue 8, Pages 1033-1040
出版商
BMJ
发表日期
2019-06-08
DOI
10.1136/annrheumdis-2018-214943
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Molecular mechanisms underpinning T helper 17 cell heterogeneity and functions in rheumatoid arthritis
- (2018) Jan Piet van Hamburg et al. JOURNAL OF AUTOIMMUNITY
- Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial
- (2018) Kim A. Papp et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Secukinumab after anti-tumour necrosis factor-α therapy: a phase III study in active rheumatoid arthritis
- (2018) E Dokoupilová et al. SCANDINAVIAN JOURNAL OF RHEUMATOLOGY
- ABT-122, a Bispecific DVD-Immunoglobulin Targeting TNF- and IL-17A, in RA With Inadequate Response to Methotrexate: A Randomized, Double-Blind Study
- (2018) Mark C. Genovese et al. Arthritis & Rheumatology
- Secukinumab in Active Rheumatoid Arthritis: A Phase III Randomized, Double-Blind, Active Comparator- and Placebo-Controlled Study
- (2017) Francisco J. Blanco et al. Arthritis & Rheumatology
- Anti-tumour necrosis factor treatment increases circulating T helper type 17 cells similarly in different types of inflammatory arthritis
- (2015) D. N. Hull et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- The Human IL-17F/IL-17A Heterodimeric Cytokine Signals through the IL-17RA/IL-17RC Receptor Complex
- (2014) J. F. Wright et al. JOURNAL OF IMMUNOLOGY
- A Phase II Randomized Study of Subcutaneous Ixekizumab, an Anti-Interleukin-17 Monoclonal Antibody, in Rheumatoid Arthritis Patients Who Were Naive to Biologic Agents or Had an Inadequate Response to Tumor Necrosis Factor Inhibitors
- (2014) Mark C. Genovese et al. Arthritis & Rheumatology
- Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extension
- (2013) Edward Keystone et al. ANNALS OF THE RHEUMATIC DISEASES
- Incomplete response of inflammatory arthritis to TNFα blockade is associated with the Th17 pathway
- (2012) Saba Alzabin et al. ANNALS OF THE RHEUMATIC DISEASES
- Systematic Review and Meta-Analysis of the Efficacy and Safety of Existing TNF Blocking Agents in Treatment of Rheumatoid Arthritis
- (2012) Kalle J. Aaltonen et al. PLoS One
- Greater likelihood of remission in rheumatoid arthritis patients treated earlier in the disease course: Results from the Consortium of Rheumatology Researchers of North America registry
- (2011) Daniel E. Furst et al. ARTHRITIS CARE & RESEARCH
- Increasing levels of circulating Th17 cells and interleukin-17 in rheumatoid arthritis patients with an inadequate response to anti-TNF-α therapy
- (2011) Der-Yuan Chen et al. ARTHRITIS RESEARCH & THERAPY
- 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative
- (2010) Daniel Aletaha et al. ARTHRITIS AND RHEUMATISM
- Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: Findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study
- (2008) Edward Keystone et al. ARTHRITIS AND RHEUMATISM
- Regulation of inflammatory responses by IL-17F
- (2008) Xuexian O. Yang et al. JOURNAL OF EXPERIMENTAL MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started